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Substantial progress has been made in the control of 
malaria during the past decade, but it is estimated that 
in 2015 there were still 429 000 deaths (uncertainty 
interval 235 000–639 000) from malaria, mainly in 
children in Africa,1 and current gains are threatened 
by the emergence of resistance to artemisinin and 
insecticides. New tools, including malaria vaccines, 
are needed. The malaria vaccine RTS,S/AS01 has so 
far attracted the most attention because it is the 
first malaria vaccine to obtain positive approval 
from a regulatory authority2 after a long period of 
development and evaluation.3 However, during 
this time, substantial progress has been made with 
the development of several other malaria vaccines, 
including the Plasmodium falciparum sporozoite (PfSPZ) 
Vaccine. 
In an Article in The Lancet Infectious Diseases, 
Mahamadou Sissoko, Sara Healy, and colleagues report 
the results of one of the first trials to investigate the 
efficacy of this vaccine in a malaria-endemic country.4 
The development of PfSPZ Vaccine has been based on 
the observation made in the 1970s that immunisation 
with irradiated sporozoites, delivered through the bites 
of more than 1000 infected mosquitoes, provided 
protection against challenge from a mosquito infected 
with viable sporozoites.5 Irradiated sporozoites under-
go partial development in liver cells to form a schizont, 
which induces an immune response, but dies before 
rupturing into the bloodstream and releasing the 
blood-stage parasites that cause the symptoms of 
malaria. Development of a vaccine based on irradiated 
sporozoites was for many years considered to be 
impractical because of the need for delivery by mosquito 
bite and to store the vaccine at a very low temperature. 
However, the team behind the PfSPZ Vaccine have 
overcome these challenges by developing novel 
methods for the production of purified sporozoite and 
for storing and distributing them with a system based 
on liquid nitrogen. Many trials of PfSPZ have now been 
done in non-immune volunteers to define an optimum 
dose and route of administration. During a recent trial in 
the USA,6 seven of ten volunteers who were immunised 
intravenously five times with 2·7 × 10⁵ sporozites 
were protected 6 months after vaccination against 
challenge with a strain of parasite homologous to that 
used in making the vaccine. However, only one of ten 
volunteers challenged with a heterologous strain—the 
kind of challenge likely to occur in malaria-endemic 
populations—was protected.6 
In the study by Sissoko, Healy, and colleagues in healthy 
adults in Mali,4 46 people in the vaccine group were 
vaccinated intravenously with five doses of 2·7 × 10⁵ 
irradiated sporozoites and 47 people in the control 
group received a saline placebo. The vaccine was safe 
highly impactful to malaria control policy. Imwong and 
colleagues provide substantial evidence that history 
is repeating itself with regard to antimalarial drug 
resistance in the case of ACT resistance.
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and extremely well tolerated, producing minimal local or 
systemic side-effects, and only one of 502 intravenous 
injections had to be repeated. Efficacy was 48·3% (95% 
CI 14·5–68·7) when measured against first infection and 
28·8% (8·2–47·2) when measured against all infections 
during the 5 month follow-up period, which is not as high 
as that seen in the volunteers in the USA. The geometric 
mean titre of antibody to the circumsporozoite protein 
on the surface of the sporozoite, a partial correlate of 
protection, was substantially lower in the volunteers 
in Mali than has previously been observed in adults in 
the USA,6 suggesting that previous exposure to malaria 
might have downregulated the immune response to the 
malaria antigens delivered through the vaccine.7 Results 
from immunological studies have provided evidence 
to support this hypothesis by showing that malaria-
exposed individuals have an increased population of 
atypical memory B cells and a depletion of follicular 
helper T cells, which are important for the development 
of immunological memory.8,9 Use of an increased dose 
of sporozites and vaccination of children before they 
are exposed to malaria are potential ways to overcome 
this challenge for PfSPZ Vaccine that are now being 
explored.10 
Although most experience has been obtained with 
sporozoites attenuated by irradiation, parallel studies 
have investigated sporozoites attenuated by genetic 
engineering11 or by inoculation of viable sporozoites 
alongside simultaneous chloroquine prophylaxis.12 
These approaches allow more complete development of 
the liver schizont than occurs with irradiated sporozoites 
and hence a broader immune response. Genetically 
modified sporozoite vaccines could be produced with 
the same manufacturing processes developed for the 
PfSPZ Vaccine.
The PfSPZ Vaccine is a very promising malaria vaccine 
candidate that is likely to be deployed first in the 
military and travellers and perhaps in mass vaccination 
campaigns targeting elimination. Whether it can 
become part of the routine expanded programme of 
immunisation in highly malaria-endemic countries, 
such as Mali, requires further research. 
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MONALISA: a grim picture of listeriosis
Listeria monocytogenes is a slow-growing food-borne 
intracellular pathogen that can cause bacteraemia, 
meningoencephalitis, and maternal–neonatal infections 
(listeriosis). Risk factors for listerial infection include the 
extremes of age (neonates and the elderly), alcoholism, 
malignancy, corticosteroid therapy, immuno sup-
pression, diabetes mellitus, liver or kidney disease, and 
iron overload.1
In The Lancet Infectious Diseases, Caroline Charlier 
and colleagues2 describe the full range and impact of 
neurolisteriosis in the largest prospective cohort study 
to date, the MONALISA study. Over a period of almost 
4 years, 818 patients with listeriosis were included in a 
nationwide surveillance based study in France, including 
107 maternal–neonatal infections, 427 patients with 
bacteraemia, and 252 with neurolisteriosis. The study 
